nodes	percent_of_prediction	percent_of_DWPC	metapath
Ticagrelor—ABCB1—Sorafenib—liver cancer	0.136	0.389	CbGbCtD
Ticagrelor—ABCB1—Doxorubicin—liver cancer	0.0827	0.236	CbGbCtD
Ticagrelor—CYP3A4—Sorafenib—liver cancer	0.0817	0.233	CbGbCtD
Ticagrelor—CYP3A4—Doxorubicin—liver cancer	0.0496	0.141	CbGbCtD
Ticagrelor—Transient ischaemic attack—Sorafenib—liver cancer	0.0168	0.0327	CcSEcCtD
Ticagrelor—Cerebral haemorrhage—Sorafenib—liver cancer	0.0153	0.0298	CcSEcCtD
Ticagrelor—Haematoma—Sorafenib—liver cancer	0.0135	0.0262	CcSEcCtD
Ticagrelor—Injection site haemorrhage—Epirubicin—liver cancer	0.0116	0.0226	CcSEcCtD
Ticagrelor—Injection site haemorrhage—Doxorubicin—liver cancer	0.0108	0.0209	CcSEcCtD
Ticagrelor—Dyspnoea exertional—Epirubicin—liver cancer	0.0104	0.0202	CcSEcCtD
Ticagrelor—Neoplasm malignant—Sorafenib—liver cancer	0.00993	0.0193	CcSEcCtD
Ticagrelor—Dyspnoea exertional—Doxorubicin—liver cancer	0.0096	0.0187	CcSEcCtD
Ticagrelor—Bone disorder—Sorafenib—liver cancer	0.00939	0.0183	CcSEcCtD
Ticagrelor—Gynaecomastia—Sorafenib—liver cancer	0.00759	0.0148	CcSEcCtD
Ticagrelor—Cardiac failure congestive—Sorafenib—liver cancer	0.00679	0.0132	CcSEcCtD
Ticagrelor—Renal failure acute—Sorafenib—liver cancer	0.00667	0.013	CcSEcCtD
Ticagrelor—Cardiac failure—Sorafenib—liver cancer	0.00631	0.0123	CcSEcCtD
Ticagrelor—Breast disorder—Sorafenib—liver cancer	0.00556	0.0108	CcSEcCtD
Ticagrelor—Gingival bleeding—Epirubicin—liver cancer	0.00552	0.0107	CcSEcCtD
Ticagrelor—Gastritis—Sorafenib—liver cancer	0.00545	0.0106	CcSEcCtD
Ticagrelor—Gingival bleeding—Doxorubicin—liver cancer	0.00511	0.00994	CcSEcCtD
Ticagrelor—Serum creatinine increased—Epirubicin—liver cancer	0.0051	0.00991	CcSEcCtD
Ticagrelor—Serum creatinine increased—Doxorubicin—liver cancer	0.00471	0.00917	CcSEcCtD
Ticagrelor—Haematemesis—Epirubicin—liver cancer	0.00451	0.00878	CcSEcCtD
Ticagrelor—Epistaxis—Sorafenib—liver cancer	0.00447	0.00871	CcSEcCtD
Ticagrelor—Lung disorder—Epirubicin—liver cancer	0.00443	0.00861	CcSEcCtD
Ticagrelor—Haemoglobin—Sorafenib—liver cancer	0.00428	0.00833	CcSEcCtD
Ticagrelor—Haemorrhage—Sorafenib—liver cancer	0.00426	0.00829	CcSEcCtD
Ticagrelor—Haemoptysis—Epirubicin—liver cancer	0.00423	0.00824	CcSEcCtD
Ticagrelor—Vaginal haemorrhage—Epirubicin—liver cancer	0.00423	0.00824	CcSEcCtD
Ticagrelor—Urinary tract disorder—Sorafenib—liver cancer	0.00421	0.00818	CcSEcCtD
Ticagrelor—Connective tissue disorder—Sorafenib—liver cancer	0.00418	0.00814	CcSEcCtD
Ticagrelor—Urethral disorder—Sorafenib—liver cancer	0.00417	0.00812	CcSEcCtD
Ticagrelor—Haematemesis—Doxorubicin—liver cancer	0.00417	0.00812	CcSEcCtD
Ticagrelor—Lung disorder—Doxorubicin—liver cancer	0.0041	0.00797	CcSEcCtD
Ticagrelor—Cardiac disorder—Sorafenib—liver cancer	0.00395	0.00769	CcSEcCtD
Ticagrelor—Vaginal haemorrhage—Doxorubicin—liver cancer	0.00392	0.00762	CcSEcCtD
Ticagrelor—Haemoptysis—Doxorubicin—liver cancer	0.00392	0.00762	CcSEcCtD
Ticagrelor—Angiopathy—Sorafenib—liver cancer	0.00386	0.00752	CcSEcCtD
Ticagrelor—Immune system disorder—Sorafenib—liver cancer	0.00385	0.00748	CcSEcCtD
Ticagrelor—Mediastinal disorder—Sorafenib—liver cancer	0.00384	0.00747	CcSEcCtD
Ticagrelor—Petechiae—Epirubicin—liver cancer	0.00381	0.00741	CcSEcCtD
Ticagrelor—Mental disorder—Sorafenib—liver cancer	0.00373	0.00726	CcSEcCtD
Ticagrelor—Malnutrition—Sorafenib—liver cancer	0.00371	0.00721	CcSEcCtD
Ticagrelor—Neoplasm malignant—Epirubicin—liver cancer	0.00367	0.00714	CcSEcCtD
Ticagrelor—Petechiae—Doxorubicin—liver cancer	0.00352	0.00686	CcSEcCtD
Ticagrelor—Rectal haemorrhage—Epirubicin—liver cancer	0.00347	0.00675	CcSEcCtD
Ticagrelor—Bone disorder—Epirubicin—liver cancer	0.00347	0.00675	CcSEcCtD
Ticagrelor—Oliguria—Epirubicin—liver cancer	0.0034	0.00662	CcSEcCtD
Ticagrelor—Neoplasm malignant—Doxorubicin—liver cancer	0.0034	0.00661	CcSEcCtD
Ticagrelor—Angioedema—Sorafenib—liver cancer	0.00339	0.00659	CcSEcCtD
Ticagrelor—Hyperuricaemia—Epirubicin—liver cancer	0.00338	0.00657	CcSEcCtD
Ticagrelor—Syncope—Sorafenib—liver cancer	0.00332	0.00647	CcSEcCtD
Ticagrelor—Loss of consciousness—Sorafenib—liver cancer	0.00326	0.00634	CcSEcCtD
Ticagrelor—Cough—Sorafenib—liver cancer	0.00323	0.00629	CcSEcCtD
Ticagrelor—Rectal haemorrhage—Doxorubicin—liver cancer	0.00321	0.00625	CcSEcCtD
Ticagrelor—Bone disorder—Doxorubicin—liver cancer	0.00321	0.00625	CcSEcCtD
Ticagrelor—Hypertension—Sorafenib—liver cancer	0.0032	0.00623	CcSEcCtD
Ticagrelor—Blood uric acid increased—Epirubicin—liver cancer	0.00319	0.00621	CcSEcCtD
Ticagrelor—Oliguria—Doxorubicin—liver cancer	0.00315	0.00612	CcSEcCtD
Ticagrelor—Unspecified disorder of skin and subcutaneous tissue—Sorafenib—liver cancer	0.00313	0.0061	CcSEcCtD
Ticagrelor—Hyperuricaemia—Doxorubicin—liver cancer	0.00313	0.00608	CcSEcCtD
Ticagrelor—Melaena—Epirubicin—liver cancer	0.00306	0.00596	CcSEcCtD
Ticagrelor—Shock—Sorafenib—liver cancer	0.00298	0.00579	CcSEcCtD
Ticagrelor—Nervous system disorder—Sorafenib—liver cancer	0.00297	0.00577	CcSEcCtD
Ticagrelor—Blood uric acid increased—Doxorubicin—liver cancer	0.00295	0.00575	CcSEcCtD
Ticagrelor—Skin disorder—Sorafenib—liver cancer	0.00294	0.00572	CcSEcCtD
Ticagrelor—Ecchymosis—Epirubicin—liver cancer	0.00283	0.00551	CcSEcCtD
Ticagrelor—Melaena—Doxorubicin—liver cancer	0.00283	0.00551	CcSEcCtD
Ticagrelor—Dyspnoea—Sorafenib—liver cancer	0.0027	0.00525	CcSEcCtD
Ticagrelor—Dyspepsia—Sorafenib—liver cancer	0.00266	0.00518	CcSEcCtD
Ticagrelor—Ecchymosis—Doxorubicin—liver cancer	0.00262	0.0051	CcSEcCtD
Ticagrelor—Gastrointestinal disorder—Sorafenib—liver cancer	0.00261	0.00508	CcSEcCtD
Ticagrelor—Fatigue—Sorafenib—liver cancer	0.00261	0.00507	CcSEcCtD
Ticagrelor—Constipation—Sorafenib—liver cancer	0.00259	0.00503	CcSEcCtD
Ticagrelor—Cardiac failure congestive—Epirubicin—liver cancer	0.00251	0.00488	CcSEcCtD
Ticagrelor—Gastrointestinal pain—Sorafenib—liver cancer	0.00247	0.00481	CcSEcCtD
Ticagrelor—Renal failure acute—Epirubicin—liver cancer	0.00246	0.00479	CcSEcCtD
Ticagrelor—Body temperature increased—Sorafenib—liver cancer	0.00239	0.00465	CcSEcCtD
Ticagrelor—Abdominal pain—Sorafenib—liver cancer	0.00239	0.00465	CcSEcCtD
Ticagrelor—Cardiac failure—Epirubicin—liver cancer	0.00233	0.00454	CcSEcCtD
Ticagrelor—Cardiac failure congestive—Doxorubicin—liver cancer	0.00232	0.00452	CcSEcCtD
Ticagrelor—Renal failure acute—Doxorubicin—liver cancer	0.00228	0.00444	CcSEcCtD
Ticagrelor—Gastrointestinal haemorrhage—Epirubicin—liver cancer	0.00228	0.00443	CcSEcCtD
Ticagrelor—Hypersensitivity—Sorafenib—liver cancer	0.00223	0.00434	CcSEcCtD
Ticagrelor—Asthenia—Sorafenib—liver cancer	0.00217	0.00422	CcSEcCtD
Ticagrelor—Cardiac failure—Doxorubicin—liver cancer	0.00216	0.0042	CcSEcCtD
Ticagrelor—Pruritus—Sorafenib—liver cancer	0.00214	0.00416	CcSEcCtD
Ticagrelor—Blood creatinine increased—Epirubicin—liver cancer	0.00213	0.00415	CcSEcCtD
Ticagrelor—Gastrointestinal haemorrhage—Doxorubicin—liver cancer	0.00211	0.0041	CcSEcCtD
Ticagrelor—Diarrhoea—Sorafenib—liver cancer	0.00207	0.00403	CcSEcCtD
Ticagrelor—Breast disorder—Epirubicin—liver cancer	0.00206	0.004	CcSEcCtD
Ticagrelor—Gastritis—Epirubicin—liver cancer	0.00201	0.00392	CcSEcCtD
Ticagrelor—Dizziness—Sorafenib—liver cancer	0.002	0.00389	CcSEcCtD
Ticagrelor—Blood creatinine increased—Doxorubicin—liver cancer	0.00197	0.00384	CcSEcCtD
Ticagrelor—Vomiting—Sorafenib—liver cancer	0.00192	0.00374	CcSEcCtD
Ticagrelor—Rash—Sorafenib—liver cancer	0.00191	0.00371	CcSEcCtD
Ticagrelor—Dermatitis—Sorafenib—liver cancer	0.00191	0.00371	CcSEcCtD
Ticagrelor—Breast disorder—Doxorubicin—liver cancer	0.0019	0.0037	CcSEcCtD
Ticagrelor—Headache—Sorafenib—liver cancer	0.0019	0.00369	CcSEcCtD
Ticagrelor—Gastritis—Doxorubicin—liver cancer	0.00186	0.00362	CcSEcCtD
Ticagrelor—Nausea—Sorafenib—liver cancer	0.0018	0.0035	CcSEcCtD
Ticagrelor—Haematuria—Epirubicin—liver cancer	0.00167	0.00325	CcSEcCtD
Ticagrelor—Epistaxis—Epirubicin—liver cancer	0.00165	0.00322	CcSEcCtD
Ticagrelor—Bradycardia—Epirubicin—liver cancer	0.0016	0.00312	CcSEcCtD
Ticagrelor—Haemoglobin—Epirubicin—liver cancer	0.00158	0.00308	CcSEcCtD
Ticagrelor—Haemorrhage—Epirubicin—liver cancer	0.00157	0.00306	CcSEcCtD
Ticagrelor—Urinary tract disorder—Epirubicin—liver cancer	0.00155	0.00302	CcSEcCtD
Ticagrelor—Oedema peripheral—Epirubicin—liver cancer	0.00155	0.00302	CcSEcCtD
Ticagrelor—Haematuria—Doxorubicin—liver cancer	0.00155	0.00301	CcSEcCtD
Ticagrelor—Connective tissue disorder—Epirubicin—liver cancer	0.00155	0.00301	CcSEcCtD
Ticagrelor—Urethral disorder—Epirubicin—liver cancer	0.00154	0.003	CcSEcCtD
Ticagrelor—Epistaxis—Doxorubicin—liver cancer	0.00153	0.00298	CcSEcCtD
Ticagrelor—Bradycardia—Doxorubicin—liver cancer	0.00148	0.00288	CcSEcCtD
Ticagrelor—Eye disorder—Epirubicin—liver cancer	0.00147	0.00286	CcSEcCtD
Ticagrelor—Haemoglobin—Doxorubicin—liver cancer	0.00146	0.00285	CcSEcCtD
Ticagrelor—Cardiac disorder—Epirubicin—liver cancer	0.00146	0.00284	CcSEcCtD
Ticagrelor—Haemorrhage—Doxorubicin—liver cancer	0.00146	0.00283	CcSEcCtD
Ticagrelor—Urinary tract disorder—Doxorubicin—liver cancer	0.00144	0.0028	CcSEcCtD
Ticagrelor—Oedema peripheral—Doxorubicin—liver cancer	0.00143	0.00279	CcSEcCtD
Ticagrelor—Connective tissue disorder—Doxorubicin—liver cancer	0.00143	0.00278	CcSEcCtD
Ticagrelor—Angiopathy—Epirubicin—liver cancer	0.00143	0.00278	CcSEcCtD
Ticagrelor—Urethral disorder—Doxorubicin—liver cancer	0.00143	0.00278	CcSEcCtD
Ticagrelor—Immune system disorder—Epirubicin—liver cancer	0.00142	0.00277	CcSEcCtD
Ticagrelor—Mediastinal disorder—Epirubicin—liver cancer	0.00142	0.00276	CcSEcCtD
Ticagrelor—Mental disorder—Epirubicin—liver cancer	0.00138	0.00268	CcSEcCtD
Ticagrelor—Malnutrition—Epirubicin—liver cancer	0.00137	0.00267	CcSEcCtD
Ticagrelor—Eye disorder—Doxorubicin—liver cancer	0.00136	0.00265	CcSEcCtD
Ticagrelor—Cardiac disorder—Doxorubicin—liver cancer	0.00135	0.00263	CcSEcCtD
Ticagrelor—Back pain—Epirubicin—liver cancer	0.00133	0.00258	CcSEcCtD
Ticagrelor—Angiopathy—Doxorubicin—liver cancer	0.00132	0.00257	CcSEcCtD
Ticagrelor—Immune system disorder—Doxorubicin—liver cancer	0.00132	0.00256	CcSEcCtD
Ticagrelor—Mediastinal disorder—Doxorubicin—liver cancer	0.00131	0.00255	CcSEcCtD
Ticagrelor—Mental disorder—Doxorubicin—liver cancer	0.00128	0.00248	CcSEcCtD
Ticagrelor—Malnutrition—Doxorubicin—liver cancer	0.00127	0.00247	CcSEcCtD
Ticagrelor—Vertigo—Epirubicin—liver cancer	0.00123	0.00239	CcSEcCtD
Ticagrelor—Syncope—Epirubicin—liver cancer	0.00123	0.00239	CcSEcCtD
Ticagrelor—Back pain—Doxorubicin—liver cancer	0.00123	0.00239	CcSEcCtD
Ticagrelor—Loss of consciousness—Epirubicin—liver cancer	0.0012	0.00234	CcSEcCtD
Ticagrelor—Cough—Epirubicin—liver cancer	0.0012	0.00233	CcSEcCtD
Ticagrelor—Hypertension—Epirubicin—liver cancer	0.00118	0.0023	CcSEcCtD
Ticagrelor—Chest pain—Epirubicin—liver cancer	0.00117	0.00227	CcSEcCtD
Ticagrelor—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—liver cancer	0.00116	0.00225	CcSEcCtD
Ticagrelor—Vertigo—Doxorubicin—liver cancer	0.00114	0.00222	CcSEcCtD
Ticagrelor—Syncope—Doxorubicin—liver cancer	0.00114	0.00221	CcSEcCtD
Ticagrelor—Confusional state—Epirubicin—liver cancer	0.00113	0.00219	CcSEcCtD
Ticagrelor—Loss of consciousness—Doxorubicin—liver cancer	0.00111	0.00217	CcSEcCtD
Ticagrelor—Cough—Doxorubicin—liver cancer	0.00111	0.00215	CcSEcCtD
Ticagrelor—Shock—Epirubicin—liver cancer	0.0011	0.00214	CcSEcCtD
Ticagrelor—Nervous system disorder—Epirubicin—liver cancer	0.0011	0.00213	CcSEcCtD
Ticagrelor—Hypertension—Doxorubicin—liver cancer	0.00109	0.00213	CcSEcCtD
Ticagrelor—Skin disorder—Epirubicin—liver cancer	0.00109	0.00211	CcSEcCtD
Ticagrelor—Chest pain—Doxorubicin—liver cancer	0.00108	0.0021	CcSEcCtD
Ticagrelor—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—liver cancer	0.00107	0.00209	CcSEcCtD
Ticagrelor—Hypotension—Epirubicin—liver cancer	0.00104	0.00203	CcSEcCtD
Ticagrelor—Confusional state—Doxorubicin—liver cancer	0.00104	0.00203	CcSEcCtD
Ticagrelor—Shock—Doxorubicin—liver cancer	0.00102	0.00198	CcSEcCtD
Ticagrelor—Nervous system disorder—Doxorubicin—liver cancer	0.00101	0.00197	CcSEcCtD
Ticagrelor—Skin disorder—Doxorubicin—liver cancer	0.001	0.00196	CcSEcCtD
Ticagrelor—Paraesthesia—Epirubicin—liver cancer	0.001	0.00195	CcSEcCtD
Ticagrelor—Dyspnoea—Epirubicin—liver cancer	0.000997	0.00194	CcSEcCtD
Ticagrelor—Dyspepsia—Epirubicin—liver cancer	0.000984	0.00191	CcSEcCtD
Ticagrelor—Hypotension—Doxorubicin—liver cancer	0.000967	0.00188	CcSEcCtD
Ticagrelor—Gastrointestinal disorder—Epirubicin—liver cancer	0.000965	0.00188	CcSEcCtD
Ticagrelor—Fatigue—Epirubicin—liver cancer	0.000964	0.00188	CcSEcCtD
Ticagrelor—Constipation—Epirubicin—liver cancer	0.000956	0.00186	CcSEcCtD
Ticagrelor—Paraesthesia—Doxorubicin—liver cancer	0.000929	0.00181	CcSEcCtD
Ticagrelor—Dyspnoea—Doxorubicin—liver cancer	0.000922	0.00179	CcSEcCtD
Ticagrelor—Feeling abnormal—Epirubicin—liver cancer	0.000921	0.00179	CcSEcCtD
Ticagrelor—Gastrointestinal pain—Epirubicin—liver cancer	0.000914	0.00178	CcSEcCtD
Ticagrelor—Dyspepsia—Doxorubicin—liver cancer	0.000911	0.00177	CcSEcCtD
Ticagrelor—Gastrointestinal disorder—Doxorubicin—liver cancer	0.000893	0.00174	CcSEcCtD
Ticagrelor—Fatigue—Doxorubicin—liver cancer	0.000892	0.00174	CcSEcCtD
Ticagrelor—Constipation—Doxorubicin—liver cancer	0.000885	0.00172	CcSEcCtD
Ticagrelor—Abdominal pain—Epirubicin—liver cancer	0.000884	0.00172	CcSEcCtD
Ticagrelor—Body temperature increased—Epirubicin—liver cancer	0.000884	0.00172	CcSEcCtD
Ticagrelor—Feeling abnormal—Doxorubicin—liver cancer	0.000853	0.00166	CcSEcCtD
Ticagrelor—Gastrointestinal pain—Doxorubicin—liver cancer	0.000846	0.00165	CcSEcCtD
Ticagrelor—Hypersensitivity—Epirubicin—liver cancer	0.000824	0.0016	CcSEcCtD
Ticagrelor—Body temperature increased—Doxorubicin—liver cancer	0.000818	0.00159	CcSEcCtD
Ticagrelor—Abdominal pain—Doxorubicin—liver cancer	0.000818	0.00159	CcSEcCtD
Ticagrelor—Asthenia—Epirubicin—liver cancer	0.000802	0.00156	CcSEcCtD
Ticagrelor—Pruritus—Epirubicin—liver cancer	0.000791	0.00154	CcSEcCtD
Ticagrelor—Diarrhoea—Epirubicin—liver cancer	0.000765	0.00149	CcSEcCtD
Ticagrelor—Hypersensitivity—Doxorubicin—liver cancer	0.000762	0.00148	CcSEcCtD
Ticagrelor—Asthenia—Doxorubicin—liver cancer	0.000742	0.00144	CcSEcCtD
Ticagrelor—Dizziness—Epirubicin—liver cancer	0.000739	0.00144	CcSEcCtD
Ticagrelor—Pruritus—Doxorubicin—liver cancer	0.000732	0.00142	CcSEcCtD
Ticagrelor—Vomiting—Epirubicin—liver cancer	0.000711	0.00138	CcSEcCtD
Ticagrelor—Diarrhoea—Doxorubicin—liver cancer	0.000708	0.00138	CcSEcCtD
Ticagrelor—Rash—Epirubicin—liver cancer	0.000705	0.00137	CcSEcCtD
Ticagrelor—Dermatitis—Epirubicin—liver cancer	0.000704	0.00137	CcSEcCtD
Ticagrelor—Headache—Epirubicin—liver cancer	0.0007	0.00136	CcSEcCtD
Ticagrelor—Dizziness—Doxorubicin—liver cancer	0.000684	0.00133	CcSEcCtD
Ticagrelor—Nausea—Epirubicin—liver cancer	0.000664	0.00129	CcSEcCtD
Ticagrelor—Vomiting—Doxorubicin—liver cancer	0.000658	0.00128	CcSEcCtD
Ticagrelor—Rash—Doxorubicin—liver cancer	0.000652	0.00127	CcSEcCtD
Ticagrelor—Dermatitis—Doxorubicin—liver cancer	0.000652	0.00127	CcSEcCtD
Ticagrelor—Headache—Doxorubicin—liver cancer	0.000648	0.00126	CcSEcCtD
Ticagrelor—P2RY12—GPCR downstream signaling—TRIO—liver cancer	0.000616	0.00454	CbGpPWpGaD
Ticagrelor—Nausea—Doxorubicin—liver cancer	0.000615	0.0012	CcSEcCtD
Ticagrelor—P2RY12—Platelet activation, signaling and aggregation—PIK3CD—liver cancer	0.000609	0.00449	CbGpPWpGaD
Ticagrelor—P2RY12—Hemostasis—IFNA1—liver cancer	0.000608	0.00449	CbGpPWpGaD
Ticagrelor—P2RY12—Platelet activation, signaling and aggregation—SERPINE1—liver cancer	0.000603	0.00445	CbGpPWpGaD
Ticagrelor—P2RY12—Platelet activation, signaling and aggregation—ALB—liver cancer	0.000601	0.00444	CbGpPWpGaD
Ticagrelor—P2RY12—GPCR downstream signaling—CCR4—liver cancer	0.00059	0.00435	CbGpPWpGaD
Ticagrelor—CYP3A4—Tryptophan metabolism—CYP2E1—liver cancer	0.000579	0.00427	CbGpPWpGaD
Ticagrelor—ABCB1—HIF-1-alpha transcription factor network—HMOX1—liver cancer	0.000573	0.00423	CbGpPWpGaD
Ticagrelor—P2RY12—Signaling by GPCR—TRIO—liver cancer	0.000559	0.00412	CbGpPWpGaD
Ticagrelor—P2RY12—Class A/1 (Rhodopsin-like receptors)—F2—liver cancer	0.000548	0.00404	CbGpPWpGaD
Ticagrelor—P2RY12—Platelet activation, signaling and aggregation—RAF1—liver cancer	0.000544	0.00401	CbGpPWpGaD
Ticagrelor—P2RY12—Hemostasis—PRKCE—liver cancer	0.000538	0.00397	CbGpPWpGaD
Ticagrelor—P2RY12—Signaling by GPCR—CCR4—liver cancer	0.000536	0.00395	CbGpPWpGaD
Ticagrelor—P2RY12—Platelet activation, signaling and aggregation—PIK3CB—liver cancer	0.000531	0.00392	CbGpPWpGaD
Ticagrelor—P2RY12—Hemostasis—ABL1—liver cancer	0.000512	0.00378	CbGpPWpGaD
Ticagrelor—P2RY12—Hemostasis—IGF2—liver cancer	0.000509	0.00376	CbGpPWpGaD
Ticagrelor—ABCB1—Transmembrane transport of small molecules—MYO5B—liver cancer	0.000496	0.00366	CbGpPWpGaD
Ticagrelor—ABCB1—Transmembrane transport of small molecules—SLC9C1—liver cancer	0.000496	0.00366	CbGpPWpGaD
Ticagrelor—P2RY12—Platelet activation, signaling and aggregation—IL2—liver cancer	0.000488	0.0036	CbGpPWpGaD
Ticagrelor—CYP3A4—Nuclear Receptors in Lipid Metabolism and Toxicity—PPARA—liver cancer	0.000485	0.00358	CbGpPWpGaD
Ticagrelor—ABCB1—Integrated Pancreatic Cancer Pathway—FST—liver cancer	0.000484	0.00357	CbGpPWpGaD
Ticagrelor—P2RY12—Hemostasis—HGF—liver cancer	0.000481	0.00355	CbGpPWpGaD
Ticagrelor—P2RY12—Hemostasis—CSF2—liver cancer	0.000476	0.00351	CbGpPWpGaD
Ticagrelor—ABCB1—HIF-1-alpha transcription factor network—TERT—liver cancer	0.00047	0.00347	CbGpPWpGaD
Ticagrelor—CYP3A4—Cytochrome P450 - arranged by substrate type—CYP2E1—liver cancer	0.000468	0.00346	CbGpPWpGaD
Ticagrelor—CYP3A4—Oxidation by Cytochrome P450—CYP2E1—liver cancer	0.000462	0.00341	CbGpPWpGaD
Ticagrelor—P2RY12—Signaling Pathways—SHC3—liver cancer	0.000446	0.00329	CbGpPWpGaD
Ticagrelor—P2RY12—GPCR ligand binding—F2—liver cancer	0.000417	0.00308	CbGpPWpGaD
Ticagrelor—CYP3A4—Tryptophan metabolism—CYP1A1—liver cancer	0.000416	0.00307	CbGpPWpGaD
Ticagrelor—P2RY12—Platelet activation, signaling and aggregation—VEGFA—liver cancer	0.000414	0.00306	CbGpPWpGaD
Ticagrelor—CYP3A4—Nuclear Receptors in Lipid Metabolism and Toxicity—PPARG—liver cancer	0.000401	0.00296	CbGpPWpGaD
Ticagrelor—P2RY12—Hemostasis—MAPK14—liver cancer	0.000385	0.00284	CbGpPWpGaD
Ticagrelor—P2RY12—Platelet activation, signaling and aggregation—TGFB1—liver cancer	0.00038	0.00281	CbGpPWpGaD
Ticagrelor—CYP3A4—Phase 1 - Functionalization of compounds—CYP2E1—liver cancer	0.00038	0.0028	CbGpPWpGaD
Ticagrelor—ABCB1—Integrated Pancreatic Cancer Pathway—HNF4A—liver cancer	0.000377	0.00278	CbGpPWpGaD
Ticagrelor—P2RY12—Hemostasis—F2—liver cancer	0.000373	0.00275	CbGpPWpGaD
Ticagrelor—CYP3A4—Biological oxidations—NR1H4—liver cancer	0.00037	0.00273	CbGpPWpGaD
Ticagrelor—ABCB1—Integrated Pancreatic Cancer Pathway—HPGDS—liver cancer	0.000369	0.00272	CbGpPWpGaD
Ticagrelor—CYP3A4—Biological oxidations—GSTA3—liver cancer	0.000364	0.00269	CbGpPWpGaD
Ticagrelor—ABCB1—Imatinib Resistance in Chronic Myeloid Leukemia—CDKN1B—liver cancer	0.000362	0.00267	CbGpPWpGaD
Ticagrelor—CYP3A4—Metapathway biotransformation—GSTA3—liver cancer	0.000359	0.00265	CbGpPWpGaD
Ticagrelor—P2RY12—Hemostasis—PIK3CG—liver cancer	0.000357	0.00264	CbGpPWpGaD
Ticagrelor—P2RY12—Signaling Pathways—FST—liver cancer	0.000346	0.00255	CbGpPWpGaD
Ticagrelor—ABCB1—HIF-1-alpha transcription factor network—SERPINE1—liver cancer	0.000345	0.00254	CbGpPWpGaD
Ticagrelor—P2RY12—GPCR downstream signaling—PRKCE—liver cancer	0.00034	0.00251	CbGpPWpGaD
Ticagrelor—CYP3A4—Cytochrome P450 - arranged by substrate type—CYP1A1—liver cancer	0.000336	0.00248	CbGpPWpGaD
Ticagrelor—CYP3A4—Biological oxidations—GSTA4—liver cancer	0.000333	0.00246	CbGpPWpGaD
Ticagrelor—CYP3A4—Oxidation by Cytochrome P450—CYP1A1—liver cancer	0.000332	0.00245	CbGpPWpGaD
Ticagrelor—P2RY12—Signaling Pathways—TRIO—liver cancer	0.00033	0.00244	CbGpPWpGaD
Ticagrelor—CYP3A4—Metapathway biotransformation—GSTA4—liver cancer	0.000328	0.00242	CbGpPWpGaD
Ticagrelor—CYP3A4—Biological oxidations—GSTA2—liver cancer	0.000324	0.00239	CbGpPWpGaD
Ticagrelor—P2RY12—Platelet activation, signaling and aggregation—PIK3CA—liver cancer	0.000324	0.00239	CbGpPWpGaD
Ticagrelor—P2RY12—Signaling Pathways—CCR4—liver cancer	0.000317	0.00234	CbGpPWpGaD
Ticagrelor—P2RY12—Hemostasis—PIK3CD—liver cancer	0.000314	0.00232	CbGpPWpGaD
Ticagrelor—CYP3A4—Biological oxidations—GSTA1—liver cancer	0.000313	0.00231	CbGpPWpGaD
Ticagrelor—P2RY12—Hemostasis—SERPINE1—liver cancer	0.000311	0.00229	CbGpPWpGaD
Ticagrelor—P2RY12—Hemostasis—ALB—liver cancer	0.00031	0.00229	CbGpPWpGaD
Ticagrelor—CYP3A4—Biological oxidations—NAT2—liver cancer	0.000309	0.00228	CbGpPWpGaD
Ticagrelor—P2RY12—Signaling by GPCR—PRKCE—liver cancer	0.000309	0.00228	CbGpPWpGaD
Ticagrelor—CYP3A4—Metapathway biotransformation—NAT2—liver cancer	0.000305	0.00225	CbGpPWpGaD
Ticagrelor—P2RY12—GPCR downstream signaling—CSF2—liver cancer	0.000301	0.00222	CbGpPWpGaD
Ticagrelor—P2RY12—Hemostasis—RAF1—liver cancer	0.00028	0.00207	CbGpPWpGaD
Ticagrelor—ABCB1—Imatinib Resistance in Chronic Myeloid Leukemia—MYC—liver cancer	0.000277	0.00204	CbGpPWpGaD
Ticagrelor—P2RY12—Hemostasis—PIK3CB—liver cancer	0.000274	0.00202	CbGpPWpGaD
Ticagrelor—P2RY12—Signaling by GPCR—CSF2—liver cancer	0.000273	0.00201	CbGpPWpGaD
Ticagrelor—CYP3A4—Phase 1 - Functionalization of compounds—CYP1A1—liver cancer	0.000273	0.00201	CbGpPWpGaD
Ticagrelor—ABCB1—HIF-1-alpha transcription factor network—JUN—liver cancer	0.000271	0.002	CbGpPWpGaD
Ticagrelor—P2RY12—Platelet activation, signaling and aggregation—AKT1—liver cancer	0.000264	0.00195	CbGpPWpGaD
Ticagrelor—CYP3A4—Metapathway biotransformation—GPX3—liver cancer	0.000259	0.00191	CbGpPWpGaD
Ticagrelor—ABCB1—Transmembrane transport of small molecules—SLC11A2—liver cancer	0.000254	0.00187	CbGpPWpGaD
Ticagrelor—P2RY12—Hemostasis—IL2—liver cancer	0.000251	0.00185	CbGpPWpGaD
Ticagrelor—P2RY12—Signaling Pathways—ADAM17—liver cancer	0.00025	0.00185	CbGpPWpGaD
Ticagrelor—CYP3A4—Biological oxidations—HPGDS—liver cancer	0.000247	0.00183	CbGpPWpGaD
Ticagrelor—ABCB1—Integrated Pancreatic Cancer Pathway—ABL1—liver cancer	0.000243	0.00179	CbGpPWpGaD
Ticagrelor—ABCB1—Transmembrane transport of small molecules—SLC40A1—liver cancer	0.000242	0.00179	CbGpPWpGaD
Ticagrelor—ABCB1—Allograft Rejection—CASP3—liver cancer	0.000242	0.00178	CbGpPWpGaD
Ticagrelor—ABCB1—Allograft Rejection—IL2—liver cancer	0.000242	0.00178	CbGpPWpGaD
Ticagrelor—ABCB1—HIF-1-alpha transcription factor network—VEGFA—liver cancer	0.000237	0.00175	CbGpPWpGaD
Ticagrelor—P2RY12—GPCR downstream signaling—F2—liver cancer	0.000236	0.00174	CbGpPWpGaD
Ticagrelor—P2RY12—Signaling Pathways—PSMA4—liver cancer	0.000235	0.00174	CbGpPWpGaD
Ticagrelor—P2RY12—Signaling Pathways—PSMD10—liver cancer	0.000235	0.00174	CbGpPWpGaD
Ticagrelor—ABCB1—Transmembrane transport of small molecules—ATP7B—liver cancer	0.000232	0.00171	CbGpPWpGaD
Ticagrelor—ABCB1—Transmembrane transport of small molecules—ANXA2—liver cancer	0.000232	0.00171	CbGpPWpGaD
Ticagrelor—P2RY12—GPCR downstream signaling—PIK3CG—liver cancer	0.000226	0.00167	CbGpPWpGaD
Ticagrelor—ABCB1—Transmembrane transport of small molecules—NR1H4—liver cancer	0.000219	0.00162	CbGpPWpGaD
Ticagrelor—P2RY12—Signaling by GPCR—F2—liver cancer	0.000214	0.00158	CbGpPWpGaD
Ticagrelor—P2RY12—Hemostasis—VEGFA—liver cancer	0.000214	0.00158	CbGpPWpGaD
Ticagrelor—ABCB1—Integrated Pancreatic Cancer Pathway—PCNA—liver cancer	0.000208	0.00154	CbGpPWpGaD
Ticagrelor—ABCB1—Allograft Rejection—VEGFA—liver cancer	0.000205	0.00151	CbGpPWpGaD
Ticagrelor—P2RY12—Signaling by GPCR—PIK3CG—liver cancer	0.000205	0.00151	CbGpPWpGaD
Ticagrelor—CYP3A4—Biological oxidations—CYP2E1—liver cancer	0.000202	0.00149	CbGpPWpGaD
Ticagrelor—CYP3A4—Metapathway biotransformation—CYP2E1—liver cancer	0.000199	0.00147	CbGpPWpGaD
Ticagrelor—P2RY12—GPCR downstream signaling—PIK3CD—liver cancer	0.000198	0.00146	CbGpPWpGaD
Ticagrelor—P2RY12—Hemostasis—TGFB1—liver cancer	0.000196	0.00145	CbGpPWpGaD
Ticagrelor—ABCB1—Allograft Rejection—TGFB1—liver cancer	0.000188	0.00139	CbGpPWpGaD
Ticagrelor—CYP3A4—Biological oxidations—GGT1—liver cancer	0.000185	0.00137	CbGpPWpGaD
Ticagrelor—ABCB1—Integrated Pancreatic Cancer Pathway—MAPK14—liver cancer	0.000183	0.00135	CbGpPWpGaD
Ticagrelor—P2RY12—Signaling Pathways—PRKCE—liver cancer	0.000182	0.00134	CbGpPWpGaD
Ticagrelor—P2RY12—Hemostasis—KRAS—liver cancer	0.000182	0.00134	CbGpPWpGaD
Ticagrelor—P2RY12—Signaling by GPCR—PIK3CD—liver cancer	0.00018	0.00133	CbGpPWpGaD
Ticagrelor—ABCB1—Integrated Pancreatic Cancer Pathway—ESR1—liver cancer	0.000179	0.00132	CbGpPWpGaD
Ticagrelor—ABCB1—Allograft Rejection—TNF—liver cancer	0.000176	0.0013	CbGpPWpGaD
Ticagrelor—ABCB1—Metabolism—UGDH—liver cancer	0.000176	0.0013	CbGpPWpGaD
Ticagrelor—P2RY12—GPCR downstream signaling—PIK3CB—liver cancer	0.000173	0.00128	CbGpPWpGaD
Ticagrelor—P2RY12—Signaling Pathways—IGF2—liver cancer	0.000173	0.00127	CbGpPWpGaD
Ticagrelor—ABCB1—Integrated Pancreatic Cancer Pathway—APC—liver cancer	0.000169	0.00125	CbGpPWpGaD
Ticagrelor—P2RY12—Hemostasis—PIK3CA—liver cancer	0.000167	0.00123	CbGpPWpGaD
Ticagrelor—CYP3A4—Biological oxidations—GSTP1—liver cancer	0.000166	0.00123	CbGpPWpGaD
Ticagrelor—ABCB1—Metabolism—EPT1—liver cancer	0.000165	0.00122	CbGpPWpGaD
Ticagrelor—CYP3A4—Metapathway biotransformation—GSTP1—liver cancer	0.000164	0.00121	CbGpPWpGaD
Ticagrelor—P2RY12—Hemostasis—TP53—liver cancer	0.000161	0.00119	CbGpPWpGaD
Ticagrelor—P2RY12—Signaling Pathways—CSF2—liver cancer	0.000161	0.00119	CbGpPWpGaD
Ticagrelor—P2RY12—Signaling by GPCR—RAF1—liver cancer	0.000161	0.00119	CbGpPWpGaD
Ticagrelor—P2RY12—Signaling Pathways—H2AFX—liver cancer	0.000159	0.00117	CbGpPWpGaD
Ticagrelor—P2RY12—GPCR downstream signaling—IL2—liver cancer	0.000159	0.00117	CbGpPWpGaD
Ticagrelor—P2RY12—Signaling by GPCR—PIK3CB—liver cancer	0.000157	0.00116	CbGpPWpGaD
Ticagrelor—ABCB1—Metabolism—TAT—liver cancer	0.000157	0.00116	CbGpPWpGaD
Ticagrelor—P2RY12—Hemostasis—HRAS—liver cancer	0.000154	0.00114	CbGpPWpGaD
Ticagrelor—CYP3A4—Biological oxidations—GSTM1—liver cancer	0.000153	0.00113	CbGpPWpGaD
Ticagrelor—ABCB1—HIF-1-alpha transcription factor network—AKT1—liver cancer	0.000151	0.00112	CbGpPWpGaD
Ticagrelor—CYP3A4—Metapathway biotransformation—GSTM1—liver cancer	0.000151	0.00111	CbGpPWpGaD
Ticagrelor—CYP3A4—Biological oxidations—CYP1A1—liver cancer	0.000145	0.00107	CbGpPWpGaD
Ticagrelor—P2RY12—Signaling by GPCR—IL2—liver cancer	0.000144	0.00106	CbGpPWpGaD
Ticagrelor—P2RY12—Signaling Pathways—TERT—liver cancer	0.000144	0.00106	CbGpPWpGaD
Ticagrelor—CYP3A4—Metapathway biotransformation—CYP1A1—liver cancer	0.000143	0.00105	CbGpPWpGaD
Ticagrelor—P2RY12—Hemostasis—AKT1—liver cancer	0.000136	0.00101	CbGpPWpGaD
Ticagrelor—ABCB1—Integrated Pancreatic Cancer Pathway—RAF1—liver cancer	0.000133	0.000981	CbGpPWpGaD
Ticagrelor—P2RY12—Signaling Pathways—KDR—liver cancer	0.000131	0.00097	CbGpPWpGaD
Ticagrelor—P2RY12—Signaling Pathways—MAPK14—liver cancer	0.000131	0.000964	CbGpPWpGaD
Ticagrelor—P2RY12—Signaling Pathways—ESR1—liver cancer	0.000128	0.000945	CbGpPWpGaD
Ticagrelor—P2RY12—Signaling Pathways—F2—liver cancer	0.000127	0.000934	CbGpPWpGaD
Ticagrelor—ABCB1—Integrated Pancreatic Cancer Pathway—CDKN1B—liver cancer	0.000122	0.000899	CbGpPWpGaD
Ticagrelor—P2RY12—Signaling Pathways—PIK3CG—liver cancer	0.000121	0.000894	CbGpPWpGaD
Ticagrelor—P2RY12—Signaling Pathways—APC—liver cancer	0.000121	0.000894	CbGpPWpGaD
Ticagrelor—ABCB1—Integrated Pancreatic Cancer Pathway—CASP3—liver cancer	0.000119	0.000881	CbGpPWpGaD
Ticagrelor—ABCB1—Integrated Pancreatic Cancer Pathway—CCND1—liver cancer	0.000116	0.000857	CbGpPWpGaD
Ticagrelor—ABCB1—Integrated Pancreatic Cancer Pathway—JUN—liver cancer	0.000116	0.000855	CbGpPWpGaD
Ticagrelor—ABCB1—Integrated Pancreatic Cancer Pathway—CTNNB1—liver cancer	0.000115	0.000849	CbGpPWpGaD
Ticagrelor—P2RY12—Signaling Pathways—BRAF—liver cancer	0.000114	0.00084	CbGpPWpGaD
Ticagrelor—ABCB1—Integrated Pancreatic Cancer Pathway—CDKN1A—liver cancer	0.000112	0.000829	CbGpPWpGaD
Ticagrelor—ABCB1—Transmembrane transport of small molecules—CYCS—liver cancer	0.000112	0.000825	CbGpPWpGaD
Ticagrelor—ABCB1—Integrated Pancreatic Cancer Pathway—MAPK8—liver cancer	0.00011	0.000809	CbGpPWpGaD
Ticagrelor—CYP3A4—Metabolism—UGDH—liver cancer	0.000108	0.000799	CbGpPWpGaD
Ticagrelor—ABCB1—Metabolism—CPT1B—liver cancer	0.000107	0.000786	CbGpPWpGaD
Ticagrelor—ABCB1—Metabolism—GLUL—liver cancer	0.000107	0.000786	CbGpPWpGaD
Ticagrelor—P2RY12—Signaling Pathways—PIK3CD—liver cancer	0.000106	0.000786	CbGpPWpGaD
Ticagrelor—P2RY12—GPCR downstream signaling—PIK3CA—liver cancer	0.000105	0.000778	CbGpPWpGaD
Ticagrelor—P2RY12—Signaling Pathways—SERPINE1—liver cancer	0.000105	0.000777	CbGpPWpGaD
Ticagrelor—P2RY12—Signaling by GPCR—KRAS—liver cancer	0.000104	0.000769	CbGpPWpGaD
Ticagrelor—ABCB1—Metabolism—NR1H4—liver cancer	0.000103	0.000758	CbGpPWpGaD
Ticagrelor—CYP3A4—Metabolism—EPT1—liver cancer	0.000102	0.000752	CbGpPWpGaD
Ticagrelor—ABCB1—Integrated Pancreatic Cancer Pathway—VEGFA—liver cancer	0.000101	0.000747	CbGpPWpGaD
Ticagrelor—ABCB1—Metabolism—GSTA3—liver cancer	0.000101	0.000745	CbGpPWpGaD
Ticagrelor—ABCB1—Transmembrane transport of small molecules—HMOX1—liver cancer	9.72e-05	0.000717	CbGpPWpGaD
Ticagrelor—CYP3A4—Metabolism—TAT—liver cancer	9.66e-05	0.000713	CbGpPWpGaD
Ticagrelor—P2RY12—Signaling by GPCR—PIK3CA—liver cancer	9.58e-05	0.000707	CbGpPWpGaD
Ticagrelor—P2RY12—Signaling Pathways—RAF1—liver cancer	9.5e-05	0.000701	CbGpPWpGaD
Ticagrelor—ABCB1—Integrated Pancreatic Cancer Pathway—MYC—liver cancer	9.32e-05	0.000688	CbGpPWpGaD
Ticagrelor—ABCB1—Integrated Pancreatic Cancer Pathway—TGFB1—liver cancer	9.3e-05	0.000686	CbGpPWpGaD
Ticagrelor—P2RY12—Signaling Pathways—PIK3CB—liver cancer	9.28e-05	0.000685	CbGpPWpGaD
Ticagrelor—P2RY12—Signaling Pathways—MTOR—liver cancer	9.28e-05	0.000685	CbGpPWpGaD
Ticagrelor—ABCB1—Metabolism—GSTA4—liver cancer	9.24e-05	0.000682	CbGpPWpGaD
Ticagrelor—ABCB1—Metabolism—GSTA2—liver cancer	9e-05	0.000664	CbGpPWpGaD
Ticagrelor—P2RY12—Signaling by GPCR—HRAS—liver cancer	8.86e-05	0.000654	CbGpPWpGaD
Ticagrelor—P2RY12—Signaling Pathways—CDKN1B—liver cancer	8.71e-05	0.000643	CbGpPWpGaD
Ticagrelor—ABCB1—Metabolism—GSTA1—liver cancer	8.69e-05	0.000641	CbGpPWpGaD
Ticagrelor—ABCB1—Integrated Pancreatic Cancer Pathway—TNF—liver cancer	8.68e-05	0.000641	CbGpPWpGaD
Ticagrelor—P2RY12—GPCR downstream signaling—AKT1—liver cancer	8.61e-05	0.000636	CbGpPWpGaD
Ticagrelor—ABCB1—Integrated Pancreatic Cancer Pathway—KRAS—liver cancer	8.61e-05	0.000635	CbGpPWpGaD
Ticagrelor—ABCB1—Metabolism—NAT2—liver cancer	8.59e-05	0.000634	CbGpPWpGaD
Ticagrelor—P2RY12—Signaling Pathways—CASP3—liver cancer	8.54e-05	0.00063	CbGpPWpGaD
Ticagrelor—P2RY12—Signaling Pathways—IL2—liver cancer	8.52e-05	0.000629	CbGpPWpGaD
Ticagrelor—P2RY12—Signaling by GPCR—IL6—liver cancer	8.48e-05	0.000626	CbGpPWpGaD
Ticagrelor—P2RY12—Signaling Pathways—CCND1—liver cancer	8.31e-05	0.000613	CbGpPWpGaD
Ticagrelor—P2RY12—Signaling Pathways—JUN—liver cancer	8.29e-05	0.000612	CbGpPWpGaD
Ticagrelor—ABCB1—Metabolism—ALDOB—liver cancer	8.23e-05	0.000608	CbGpPWpGaD
Ticagrelor—P2RY12—Signaling Pathways—CTNNB1—liver cancer	8.23e-05	0.000607	CbGpPWpGaD
Ticagrelor—P2RY12—Signaling Pathways—MMP9—liver cancer	8.07e-05	0.000595	CbGpPWpGaD
Ticagrelor—P2RY12—Signaling Pathways—CDKN1A—liver cancer	8.04e-05	0.000593	CbGpPWpGaD
Ticagrelor—ABCB1—Integrated Pancreatic Cancer Pathway—PIK3CA—liver cancer	7.91e-05	0.000584	CbGpPWpGaD
Ticagrelor—ABCB1—Metabolism—CRABP1—liver cancer	7.86e-05	0.00058	CbGpPWpGaD
Ticagrelor—ABCB1—Transmembrane transport of small molecules—PPARA—liver cancer	7.85e-05	0.000579	CbGpPWpGaD
Ticagrelor—P2RY12—Signaling Pathways—MAPK8—liver cancer	7.84e-05	0.000579	CbGpPWpGaD
Ticagrelor—P2RY12—Signaling by GPCR—AKT1—liver cancer	7.82e-05	0.000577	CbGpPWpGaD
Ticagrelor—ABCB1—Integrated Pancreatic Cancer Pathway—TP53—liver cancer	7.65e-05	0.000565	CbGpPWpGaD
Ticagrelor—P2RY12—Signaling Pathways—VEGFA—liver cancer	7.24e-05	0.000534	CbGpPWpGaD
Ticagrelor—P2RY12—Signaling Pathways—STAT3—liver cancer	7.17e-05	0.000529	CbGpPWpGaD
Ticagrelor—ABCB1—Metabolism—HPGDS—liver cancer	6.87e-05	0.000507	CbGpPWpGaD
Ticagrelor—P2RY12—Signaling Pathways—MYC—liver cancer	6.66e-05	0.000492	CbGpPWpGaD
Ticagrelor—P2RY12—Signaling Pathways—TGFB1—liver cancer	6.65e-05	0.00049	CbGpPWpGaD
Ticagrelor—CYP3A4—Metabolism—GLUL—liver cancer	6.57e-05	0.000484	CbGpPWpGaD
Ticagrelor—CYP3A4—Metabolism—CPT1B—liver cancer	6.57e-05	0.000484	CbGpPWpGaD
Ticagrelor—ABCB1—Integrated Pancreatic Cancer Pathway—AKT1—liver cancer	6.46e-05	0.000477	CbGpPWpGaD
Ticagrelor—CYP3A4—Metabolism—NR1H4—liver cancer	6.33e-05	0.000467	CbGpPWpGaD
Ticagrelor—CYP3A4—Metabolism—GSTA3—liver cancer	6.22e-05	0.000459	CbGpPWpGaD
Ticagrelor—P2RY12—Signaling Pathways—KRAS—liver cancer	6.16e-05	0.000454	CbGpPWpGaD
Ticagrelor—ABCB1—Metabolism—PSMA4—liver cancer	6.12e-05	0.000452	CbGpPWpGaD
Ticagrelor—ABCB1—Metabolism—PSMD10—liver cancer	6.12e-05	0.000452	CbGpPWpGaD
Ticagrelor—ABCB1—Metabolism—GOT2—liver cancer	5.95e-05	0.000439	CbGpPWpGaD
Ticagrelor—ABCB1—Transmembrane transport of small molecules—ALB—liver cancer	5.84e-05	0.000431	CbGpPWpGaD
Ticagrelor—CYP3A4—Metabolism—GSTA4—liver cancer	5.69e-05	0.00042	CbGpPWpGaD
Ticagrelor—P2RY12—Signaling Pathways—PIK3CA—liver cancer	5.66e-05	0.000417	CbGpPWpGaD
Ticagrelor—ABCB1—Metabolism—CYP2E1—liver cancer	5.6e-05	0.000413	CbGpPWpGaD
Ticagrelor—CYP3A4—Metabolism—GSTA2—liver cancer	5.55e-05	0.000409	CbGpPWpGaD
Ticagrelor—P2RY12—Signaling Pathways—TP53—liver cancer	5.47e-05	0.000404	CbGpPWpGaD
Ticagrelor—CYP3A4—Metabolism—GSTA1—liver cancer	5.35e-05	0.000395	CbGpPWpGaD
Ticagrelor—CYP3A4—Metabolism—NAT2—liver cancer	5.29e-05	0.00039	CbGpPWpGaD
Ticagrelor—ABCB1—Transmembrane transport of small molecules—RAF1—liver cancer	5.28e-05	0.000389	CbGpPWpGaD
Ticagrelor—ABCB1—Metabolism—CYCS—liver cancer	5.24e-05	0.000386	CbGpPWpGaD
Ticagrelor—P2RY12—Signaling Pathways—HRAS—liver cancer	5.23e-05	0.000386	CbGpPWpGaD
Ticagrelor—ABCB1—Metabolism—GOT1—liver cancer	5.14e-05	0.000379	CbGpPWpGaD
Ticagrelor—ABCB1—Metabolism—GGT1—liver cancer	5.14e-05	0.000379	CbGpPWpGaD
Ticagrelor—CYP3A4—Metabolism—ALDOB—liver cancer	5.07e-05	0.000374	CbGpPWpGaD
Ticagrelor—P2RY12—Signaling Pathways—IL6—liver cancer	5.01e-05	0.00037	CbGpPWpGaD
Ticagrelor—CYP3A4—Metabolism—CRABP1—liver cancer	4.84e-05	0.000357	CbGpPWpGaD
Ticagrelor—P2RY12—Signaling Pathways—AKT1—liver cancer	4.62e-05	0.000341	CbGpPWpGaD
Ticagrelor—ABCB1—Metabolism—GSTP1—liver cancer	4.62e-05	0.000341	CbGpPWpGaD
Ticagrelor—ABCB1—Metabolism—HMOX1—liver cancer	4.55e-05	0.000336	CbGpPWpGaD
Ticagrelor—ABCB1—Metabolism—GSTM1—liver cancer	4.24e-05	0.000313	CbGpPWpGaD
Ticagrelor—CYP3A4—Metabolism—HPGDS—liver cancer	4.23e-05	0.000312	CbGpPWpGaD
Ticagrelor—ABCB1—Metabolism—CYP1A1—liver cancer	4.02e-05	0.000297	CbGpPWpGaD
Ticagrelor—CYP3A4—Metabolism—PSMA4—liver cancer	3.77e-05	0.000278	CbGpPWpGaD
Ticagrelor—CYP3A4—Metabolism—PSMD10—liver cancer	3.77e-05	0.000278	CbGpPWpGaD
Ticagrelor—ABCB1—Metabolism—MTHFR—liver cancer	3.75e-05	0.000277	CbGpPWpGaD
Ticagrelor—ABCB1—Metabolism—PPARA—liver cancer	3.68e-05	0.000271	CbGpPWpGaD
Ticagrelor—CYP3A4—Metabolism—GOT2—liver cancer	3.67e-05	0.000271	CbGpPWpGaD
Ticagrelor—CYP3A4—Metabolism—CYP2E1—liver cancer	3.45e-05	0.000254	CbGpPWpGaD
Ticagrelor—CYP3A4—Metabolism—CYCS—liver cancer	3.23e-05	0.000238	CbGpPWpGaD
Ticagrelor—CYP3A4—Metabolism—GOT1—liver cancer	3.17e-05	0.000234	CbGpPWpGaD
Ticagrelor—CYP3A4—Metabolism—GGT1—liver cancer	3.17e-05	0.000234	CbGpPWpGaD
Ticagrelor—ABCB1—Metabolism—PIK3CG—liver cancer	3.15e-05	0.000232	CbGpPWpGaD
Ticagrelor—ABCB1—Metabolism—PPARG—liver cancer	3.04e-05	0.000224	CbGpPWpGaD
Ticagrelor—CYP3A4—Metabolism—GSTP1—liver cancer	2.84e-05	0.00021	CbGpPWpGaD
Ticagrelor—CYP3A4—Metabolism—HMOX1—liver cancer	2.8e-05	0.000207	CbGpPWpGaD
Ticagrelor—ABCB1—Metabolism—PIK3CD—liver cancer	2.77e-05	0.000204	CbGpPWpGaD
Ticagrelor—ABCB1—Metabolism—ALB—liver cancer	2.73e-05	0.000202	CbGpPWpGaD
Ticagrelor—CYP3A4—Metabolism—GSTM1—liver cancer	2.61e-05	0.000193	CbGpPWpGaD
Ticagrelor—CYP3A4—Metabolism—CYP1A1—liver cancer	2.48e-05	0.000183	CbGpPWpGaD
Ticagrelor—ABCB1—Metabolism—PIK3CB—liver cancer	2.41e-05	0.000178	CbGpPWpGaD
Ticagrelor—CYP3A4—Metabolism—MTHFR—liver cancer	2.31e-05	0.00017	CbGpPWpGaD
Ticagrelor—CYP3A4—Metabolism—PPARA—liver cancer	2.27e-05	0.000167	CbGpPWpGaD
Ticagrelor—CYP3A4—Metabolism—PIK3CG—liver cancer	1.94e-05	0.000143	CbGpPWpGaD
Ticagrelor—CYP3A4—Metabolism—PPARG—liver cancer	1.87e-05	0.000138	CbGpPWpGaD
Ticagrelor—CYP3A4—Metabolism—PIK3CD—liver cancer	1.71e-05	0.000126	CbGpPWpGaD
Ticagrelor—CYP3A4—Metabolism—ALB—liver cancer	1.68e-05	0.000124	CbGpPWpGaD
Ticagrelor—CYP3A4—Metabolism—PIK3CB—liver cancer	1.49e-05	0.00011	CbGpPWpGaD
Ticagrelor—ABCB1—Metabolism—PIK3CA—liver cancer	1.47e-05	0.000109	CbGpPWpGaD
Ticagrelor—ABCB1—Metabolism—AKT1—liver cancer	1.2e-05	8.87e-05	CbGpPWpGaD
Ticagrelor—CYP3A4—Metabolism—PIK3CA—liver cancer	9.07e-06	6.69e-05	CbGpPWpGaD
Ticagrelor—CYP3A4—Metabolism—AKT1—liver cancer	7.41e-06	5.46e-05	CbGpPWpGaD
